- Home
- EPM vs SKYE Comparison
EPM vs SKYE Comparison
Compare EPM & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPM
- SKYE
- Stock Information
- Founded
- EPM 2003
- SKYE 2012
- Country
- EPM United States
- SKYE United States
- Employees
- EPM N/A
- SKYE N/A
- Industry
- EPM Oil & Gas Production
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- EPM Energy
- SKYE Health Care
- Exchange
- EPM Nasdaq
- SKYE Nasdaq
- Market Cap
- EPM 164.3M
- SKYE 73.4M
- IPO Year
- EPM 1996
- SKYE N/A
- Fundamental
- Price
- EPM $5.00
- SKYE $4.52
- Analyst Decision
- EPM Hold
- SKYE Buy
- Analyst Count
- EPM 1
- SKYE 6
- Target Price
- EPM $4.50
- SKYE $16.60
- AVG Volume (30 Days)
- EPM 207.6K
- SKYE 2.0M
- Earning Date
- EPM 05-13-2025
- SKYE 08-08-2025
- Dividend Yield
- EPM 9.60%
- SKYE N/A
- EPS Growth
- EPM N/A
- SKYE N/A
- EPS
- EPM N/A
- SKYE N/A
- Revenue
- EPM $85,959,000.00
- SKYE N/A
- Revenue This Year
- EPM $2.62
- SKYE N/A
- Revenue Next Year
- EPM $4.53
- SKYE N/A
- P/E Ratio
- EPM N/A
- SKYE N/A
- Revenue Growth
- EPM 3.79
- SKYE N/A
- 52 Week Low
- EPM $4.05
- SKYE $1.14
- 52 Week High
- EPM $6.14
- SKYE $7.60
- Technical
- Relative Strength Index (RSI)
- EPM 58.28
- SKYE 74.70
- Support Level
- EPM $4.66
- SKYE $3.41
- Resistance Level
- EPM $5.04
- SKYE $5.75
- Average True Range (ATR)
- EPM 0.18
- SKYE 0.60
- MACD
- EPM -0.01
- SKYE 0.17
- Stochastic Oscillator
- EPM 63.16
- SKYE 69.27
About EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent oil and gas company operating in the United States. It is engaged predominantly in the acquisition, exploitation, and development of properties for the production of crude oil and natural gas, onshore in the United States. The company's revenues are generated from its crude oil, natural gas, and NGL production from the Jonah Field in Sublette County, Wyoming; the Williston Basin in North Dakota; the Barnett Shale located in North Texas; the Hamilton Dome Field in Wyoming; and the Delhi Field in Northeast Louisiana.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.